GENITAL TRICHOMONAS VAGINALIS IS RARE AMONG FEMALE ATTENDEES AT A SYDNEY METROPOLITAN SEXUAL HEALTH CLINIC

Tilley DM1,2, Dubedat SM3, Lowe P4, Templeton DJ1,5,6
1Sexual Health Service, Community Health, Sydney Local Health District, Sydney, Australia
2Women’s Health Service, Community Health, Sydney Local Health District, Sydney, Australia
3Department of Microbiology, Royal Prince Alfred Hospital, Sydney, Australia
4Hologic (Australia) Pty Ltd 5The Kirby Institute, University of New South Wales, Sydney, Australia
6Central Clinical School, The University of Sydney, Sydney, Australia

Background

Trichomonas vaginalis (TV) is the most common non-viral sexually transmitted infection worldwide, however, it is not a notifiable infection in Australia.

Among Australian women, reported NAAT-diagnosed prevalence varies widely (0.38%-8.4%).

TV is associated with pelvic inflammatory disease, preterm delivery and an elevated risk of HIV transmission.

In women, more than half (50-80%) of the TV infections are asymptomatic.

Nucleic acid amplification tests (NAAT) are more sensitive than wet-film and are the optimal diagnostic method in developed countries.

Aim

To assess whether routine NAAT testing for genital TV in females is indicated in an urban Australian setting.

Methods

Cross-sectional study of female attendees at RPA Sexual Health, a publicly-funded sexual health clinic in Sydney, from July 2013 to February 2014.

First void urine or endocervical specimens tested for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) were eligible for TV testing.

Testing was performed by transcription-mediated amplification using the Aptima Trichomonas vaginalis assay (Hologic Inc., United States).

Characteristics of women tested and not tested for TV were extracted from the clinic database and compared by Chi-squared test.

Approval was obtained from the SLHD Ethics Review Committee (RPAH Zone).

Results

393 women tested for CT/NG at 471 presentations.

347 TV tests performed at almost three-quarters (73.7%) of presentations.

Among all presentations, almost half (n=224, 47.6%) complained of genital symptoms.

There were no significant differences between women who had (n=294), and did not have (n=99), a TV test during the study period, except that women who had recent overseas sexual contact were less likely to be tested (Table 1).

Of the 347 tests, two TV infections were diagnosed, a positivity rate of 0.6% (95% CI 0.07-2.1%).

Both TV cases were Australian-born with a history of injecting drug use in the past 12 months, neither were sex workers and one identified as Aboriginal. One presented with post-coital bleeding, and TV was identified on wet film. The other reported pelvic symptoms, but was tested on outreach and no wet film microscopy was performed. Neither had concurrent CT/NG infections detected or clinical cervicitis diagnosed on examination.

Discussion

We found a low overall TV positivity rate among asymptomatic women.

Our positivity rate is similar to the NAAT-detected TV prevalence reported previously at another sexual health clinic in Sydney, but substantially lower than the 4.8% prevalence found in another Sydney-based study. This may reflect the use of a different in-house NAAT in that study, and their inclusion criterion of clinical cervicitis.

TV infection in men is not commonly associated with adverse clinical outcomes; therefore men were not included in this study.

There were a number of limitation: small number of TV infections precluding analysis of demographic and behavioral associations, eligible specimens identified by the laboratory and staff changes during the study period resulted in a quarter of CT/NG specimens not being tested for TV.

Women reporting recent overseas sexual contact were less likely to be tested and since many overseas countries have a higher TV prevalence than Australia, TV positivity could have been underestimated.

The findings are unlikely to be generalisable to rural and remote Australian settings, where TV prevalence is higher, and disproportionately affects Aboriginal communities.

Conclusions

Intermittent surveillance of TV prevalence at sexual health clinics may be useful to identify trends and monitor disease burden in Australian community settings.

Our findings are in accord with those from previous urban Australian studies and do not support routine TV testing among asymptomatic female sexual health clinic attendees in metropolitan Sydney.

Table 1: Demographic and behavioural characteristics of 393 women attending RPA Sexual Health during the study period

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>TV test n (%)</th>
<th>no TV test n (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total women</td>
<td>294 (74.8%)</td>
<td>99 (25.2%)</td>
<td></td>
</tr>
<tr>
<td>Age (median, years)</td>
<td>27 (range 16-62)</td>
<td>28 (range 16-61)</td>
<td>0.112</td>
</tr>
<tr>
<td>Born in Australia</td>
<td>155 (52.7%)</td>
<td>59 (59.6%)</td>
<td>0.235</td>
</tr>
<tr>
<td>Aboriginal or Torres Strait Islander</td>
<td>8 (2.7%)</td>
<td>2 (2.0%)</td>
<td>0.702</td>
</tr>
<tr>
<td>Culturally and linguistically diverse background</td>
<td>66 (22.4%)</td>
<td>18 (18.2%)</td>
<td>0.370</td>
</tr>
<tr>
<td>Language other than English preferred</td>
<td>15 (5.1%)</td>
<td>2 (2.0%)</td>
<td>0.192</td>
</tr>
<tr>
<td>Sex work in past 12 months</td>
<td>64 (21.8%)</td>
<td>15 (15.2%)</td>
<td>0.155</td>
</tr>
<tr>
<td>Injecting drug use in past 12 months</td>
<td>24 (13.6%)</td>
<td>9 (9.1%)</td>
<td>0.773</td>
</tr>
<tr>
<td>Sexual contact with women in past 12 months</td>
<td>42 (14.3%)</td>
<td>10 (10.1%)</td>
<td>0.302</td>
</tr>
<tr>
<td>Sex overseas in past 12 months</td>
<td>40 (13.6%)</td>
<td>27 (27.3%)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Disclosure of Interest Statement

Aptima Trichomonas vaginalis assay testing kits were provided free by Hologic (Australia) Pty Ltd.

Acknowledgements

The authors would like to acknowledge Susanne Iacopini and Hanishah Corner for assistance with data collection.